In prostate cancer, oncogenic alterations in PIK3CA and AR were enriched in TMB and bTMB≥10 samples, whereas TMPRSS2-ERG fusions were more likely to be found in TMB and bTMB<10 samples (Fig. 3D). This evidence concerns the gene AR and prostate carcinoma.